Pharma Patent Expirations Report 2026–2032: Blockbuster Drugs, Revenue at Risk and Generic Entry Opportunities

Pharmaceutical patent expirations are becoming a critical strategic issue for originator drug manufacturers, generic pharmaceutical companies, biosimilar developers, contract development and manufacturing organizations (CDMOs), and active pharmaceutical ingredient (API) suppliers.

Between 2026 and 2032, more than $500 billion in worldwide prescription-drug sales could be exposed to generic competition, according to industry forecasts reported in October 2026. However, the actual impact will depend on patent litigation, settlement agreements, regulatory approvals, secondary patents, manufacturing readiness and the timing of competitor launches.

For pharmaceutical businesses, patent expiration is not simply an intellectual property event. It creates a series of commercial decisions: which products to develop, which manufacturing capabilities to build, where to secure licenses, and which markets to enter first.

Download In depth Sample: https://www.towardshealthcare.com/download-sample/5341 

Key Statistics on the Pharma Patent Cliff

Major Pharmaceutical Drugs Approaching Loss of Exclusivity

The following examples illustrate how patent dates, expected generic or biosimilar entry, and revenue exposure can differ. The dates below focus on the United States unless stated otherwise.

Sources: Pharma Patent Cliff tracker and the 2025 annual filings of Merck, Pfizer and Eli Lilly. Sales represent worldwide product sales reported for 2025, not the revenue that will necessarily disappear when US exclusivity ends.

These examples show why pharmaceutical companies need product-level patent intelligence rather than a simple list of expiration years. A compound patent may expire before formulation, manufacturing or method-of-use patents. Settlements can also establish a later date for generic entry.

Sources: Pharma Patent Cliff data, Merck 2025 Form 10-K, Pfizer 2025 Form 10-K, Eli Lilly 2025 Form 10-K.

2026–2028: Where Competitive Pressure Is Building First

1. 2026: Generic Competition and Established Exclusivity Losses

Several products entered or approached significant exclusivity milestones during 2026. Merck identified Januvia and Janumet as losing US market exclusivity in May 2026, with Janumet XR following in July. The company also anticipated losing US market exclusivity for Bridion in July 2026.

These products illustrate a central commercial reality: the opportunity for generic manufacturers depends not only on patent dates but also on the competitive landscape already established through settlements, regulatory filings and launch preparation.

For customized pharmaceutical intelligence, company datasets, competitive analysis and buyer identification, contact [email protected].

For generic developers, near-term priorities include evaluating existing approvals, manufacturing capacity, pricing pressure and distribution readiness. API suppliers may also assess demand from companies preparing launches, while originator manufacturers must plan for potential erosion in sales and profitability.

Source: Merck 2025 Form 10-K.

2. 2027: Oncology and Diabetes Products

The 2027 pipeline of exclusivity events includes Xtandi, Ibrance and Trulicity in the US patent schedules tracked by industry sources.

• Xtandi: A prostate cancer treatment commercialized by Astellas and Pfizer. Its US patent timeline creates a reason for generic developers to examine litigation status, manufacturing feasibility and the potential launch window.

• Ibrance: Pfizer's breast cancer treatment. The listed US basic patent year is 2027, although pediatric exclusivity and other patent considerations affect the practical entry date.

• Trulicity: Eli Lilly's injectable diabetes medicine. Its US compound patent and biologics data protection are listed for 2027, making it relevant to companies evaluating biologic competition and manufacturing requirements.

Patent milestones do not automatically authorize a competitor to launch. Regulatory review, patent disputes, settlement provisions and additional exclusivities can change the actual date.

Sources: Pfizer 2025 Form 10-K, Eli Lilly 2025 Form 10-K.

3. 2028: Keytruda, Eliquis and Opdivo

The tracked 2028 US exclusivity-loss group represents $71 billion in 2025 worldwide sales across seven drugs, led by Keytruda, Eliquis and Opdivo.

Keytruda is particularly important because of its revenue scale. Merck's 2025 annual filing lists December 2028 for its primary US compound patent, with related patents extending into 2029. The company has said it expects biosimilar competition to materially affect sales during 2028–2029.

For biosimilar developers, this creates a significant long-term planning case involving development timelines, clinical and regulatory evidence, manufacturing capacity, launch strategy and payer access. For Merck and its partners, the focus is on protecting the franchise, advancing follow-on formulations and building replacement revenue.

Eliquis demonstrates a different situation: patent expiration and actual generic launch timing are not necessarily the same. Litigation outcomes and settlement agreements influence when competitors can enter.

Source: Merck 2025 Form 10-K, Pharma Patent Cliff key figures.

What Patent Expirations Mean for Different Industry Participants

Generic Pharmaceutical Manufacturers

Generic manufacturers can use patent-expiration intelligence to prioritize products based on annual sales, the number of likely competitors, dosage-form complexity, manufacturing requirements and regulatory status.

Products with substantial existing demand may attract multiple applicants. Commercial success therefore depends on more than being among the first companies to develop a copy. Manufacturing cost, reliable supply, regulatory compliance, distribution and access to buyers also influence outcomes.

Biosimilar Developers

Biosimilar opportunities often require longer development cycles and more complex manufacturing than conventional small-molecule generics. Companies evaluating oncology and immunology biologics need to assess analytical comparability, clinical evidence requirements, manufacturing scale, intellectual property disputes and the expected competitive launch window.

Keytruda is an important example of a high-revenue biologic franchise that warrants long-range assessment, but its patent dates should not be interpreted as a guaranteed biosimilar launch date.

API Suppliers and CDMOs

Patent expirations can create demand for APIs, intermediates, formulation development, analytical testing, technology transfer and commercial manufacturing services.

Suppliers should assess:

• Which generic or biosimilar developers are actively preparing for entry.

• Whether the product requires specialized synthesis, containment or sterile manufacturing.

• The number of potential customers and the expected price competition.

• Whether regulatory inspections, technical documentation and capacity can be completed before the expected launch.

• Whether demand is concentrated in the US, Europe, India or other individual territories.

Originator Pharmaceutical Companies

Originator manufacturers need to estimate how quickly sales may decline after competitor entry and identify replacement revenue before exclusivity weakens.

Potential responses include launching new indications, developing improved formulations, strengthening lifecycle management, licensing external assets, acquiring complementary products and prioritizing new clinical programs.

The most effective strategy depends on the size of the exposed franchise, the strength of the remaining pipeline and the speed at which competitors can establish supply.

Where the Commercial Opportunities Are Emerging

1. Product prioritization for generic entry

Compare products by sales exposure, expected US exclusivity loss, patent litigation, dosage forms, number of competitors and development complexity. This can help manufacturers prioritize products with a feasible route to launch.

2. Biosimilar development and manufacturing partnerships

Identify biologics approaching exclusivity loss, assess biosimilar developers and manufacturing partners, and evaluate the technical and commercial requirements for entering specific territories.

3. API and intermediate supply opportunities

Map potential generic entrants to their sourcing needs. Suppliers can use product-level intelligence to identify companies likely to require APIs, intermediates, process development or commercial-scale production.

4. Licensing and portfolio expansion

Originator companies and emerging pharmaceutical businesses can use patent intelligence to evaluate licensing candidates, in-licensing opportunities, product acquisitions and portfolio gaps.

5. Regional launch planning

US patent dates should not be treated as global dates. Patent protection, regulatory exclusivity, litigation and settlement terms vary by country. Companies need territory-specific timelines to prioritize launches and avoid unsupported assumptions about entry.

Why a Patent Expiration Date Is Not the Same as a Launch Date

A reliable patent-expiration report should distinguish among four separate milestones:

• Patent expiry: The end of protection under a particular patent.

• Loss of regulatory exclusivity: The end of a separate period of protection granted under regulatory rules.

• Expected generic or biosimilar entry: The earliest practical launch window, based on the applicable patent position, litigation and settlements.

• Actual launch: The point when a competing product becomes commercially available in the relevant country.

A single medicine may have different dates across the United States, Europe, Japan, China and India. Additional formulation or manufacturing patents may also affect competition after a primary compound patent expires.

For that reason, patent intelligence should be validated against company filings, official patent registers, regulatory databases and relevant litigation or settlement disclosures. Forecasts should clearly distinguish confirmed events from estimates.

How Towards Healthcare Supports Pharmaceutical Patent Intelligence

Towards Healthcare Research & Consulting helps pharmaceutical decision-makers evaluate competitive positioning and commercial opportunities through structured company and product intelligence.

Relevant areas of support include:

• Complete Master Datasets: Product, company, therapeutic-area and competitive intelligence.

• Pipeline Intelligence: Assessment of development programs, potential competitors and product portfolios.

• Competitive Quadrants: Comparison of companies by capabilities, portfolio strength and strategic positioning.

• Buyer Identification: Identification of potential pharmaceutical buyers, licensing partners, API customers and manufacturing partners.

• Customized Dashboards: Tracking of patent milestones, company activity, product launches and regional opportunities.

• GTM Strategy: Support for product prioritization, regional launch planning, partnership development and commercial entry.

A well-structured pharma patent expirations report can help companies move from tracking patent dates to identifying specific development, manufacturing, licensing and business development opportunities.

About Us

Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram